This study examines the link between vascular endothelial growth factor inhibitors (VEGFi) and VEGF receptor inhibitors (VEGFRi) used in treating malignant tumors and the incidence of thrombotic microangiopathy (TMA). This evidence concerns the gene VEGFA and cancer.